Overview
Any contamination introduced during the production of biologicals can pose significant potential safety risks for patients. Biopharmaceutical manufacturers must understand the most effective methods for quickly identifying sources of such contamination, particularly when developing cell and gene therapies. By doing so, it’s possible to reduce contamination risk, and cut down on costly product recalls.
Objective
In this invaluable discussion, Daniel Tatarsky will host a conversation on tracking contaminants in the biomanufacturing process as per European Pharmacopoeia and USP. Firstly, our experts will provide an overview of the contamination risks, then they will provide an in-depth review of the latest mycoplasma testing techniques. They will cover both rapid and culture methods as well as adventitious virus testing using molecular and virology methods.
Agenda
Target Audience: The webinar is aimed at all experts involved in manufacturing for biopharmaceutical companies.
Language: English
Can't make a live session? Register now and receive a complimentary recording after the live event. For further information, please contact: healthscience@sgs.com